Omalizumab
- PDF / 169,358 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 98 Downloads / 162 Views
1 S
Acute motor conduction block neuropathy: case report A 45-year-old patient [sex not stated] developed acute motor conduction block neuropathy during treatment with omalizumab. The asthmatic patient was admitted with acute quadriparesis, one week after the first dose of omalizumab [route and dosage not stated]. On admission, clinical findings showed that the patient had acute quadriparesis, which had occurred 1 week after the first dose of omalizumab, and the patient had no sensory, bulbar or cranial nerve affection. MRI was free. Electrophysiological findings indicated acute motor conduction block neuropathy. CSF showed protein 60 and cells 7 with negative antigangliosides antibodies. The patient received immune globulin with poor response. Thereafter, the patient underwent extensive rehabilitation. On 1 year follow-up, the patient became ambulant and nerve conduction study showed resolution of the conduction block with decreased compound muscle action potential in ulnar and tibial nerves bilaterally with signs of denervation. Elshony H, et al. Omalizumab Induced Acute Motor Conduction Block Neuropathy: Case report and literature review. European Journal of Neurology 27 (Suppl. 1): 754 (plus 803498420 poster) abstr. EPO1363, May 2020. Available from: URL: https://onlinelibrary.wiley.com/toc/14681331/2020/27/S1 [abstract]
0114-9954/20/1819-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 29 Aug 2020 No. 1819
Data Loading...
